|
|
|
| Effect of Levetiracetam on children with febrile seizure and its effect on expression of neuron-specific enolase and S-100β protein in serum |
| DING Hongfei1 ZHU Xianglan1 ZHANG Xiao′an1 WANG Yeping2 CHEN Peng3 DONG Ling3 ZHUO Chao1 |
1.Department of Pediatrics, Changxing People′s Hospital of Zhejiang Province (Changxing Hospital, the Second Affiliated Hospital of Zhejiang University Medical College), Zhejiang Province, Changxing 313100, China;
2.Department of Clinical Laboratory, Changxing People′s Hospital of Zhejiang Province (Changxing Hospital, the Second Affiliated Hospital of Zhejiang University Medical College), Zhejiang Province, Changxing 313100, China;
3.Deparement of Clinical Laboratory, the First Affiliated Hospital of Wannan Medical College of Anhui Province, Anhui Province, Wannan 241001, China |
|
|
|
Abstract Objective To investigate the effect of Levetiracetam on children with febrile seizure (FS) and its effect on the expression of neuron-specific enolase (NSE) and S-100 Mongolian protein (S-100β) in serum. Methods From November 2017 to April 2019, 70 children with FS in Department of Pediatrics, Changxing People′s Hospital of Zhejiang Province were selected as the study objects, According to the random number table method, the patients were divided into control group and observation group, 35 cases in each group. The control group was treated with oral Diazepam Tablets, while the observation group was treated with oral Levetiracetam Tablets. The course of treatment was set as 3 d. After one course of treatment, the patients were followed up for 6 months to 1 year. The recurrence rate of convulsion and incidence of adverse reactions were compared between the two groups. NSE and S-100 were measured before and after treatment. Results During the study and follow-up, 5 patients in the control group dropped out due to active withdrawal, poor compliance and follow-up release, while 3 patients in the observation group dropped out. In order to maintain the quantity balance, 30 patients were eventually included in each group. Follow-up for 6 months to 1 year showed no statistically significant difference in the recurrence rate of convulsion between the two groups (P ＞ 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P ＜ 0.05). Before treatment, there was no significant difference in NSE and S-100 between the two groups (P ＞ 0.05). NSE and S-100 in both groups were lower than those before treatment, and NSE and S-100 in the observation group were lower than those in the control group, with statistically significant differences (all P ＜ 0.05). Conclusion Levetiracetam can effectively prevent FS recurrence, and its relapse prevention effect is equivalent to that of Diazepam. With high clinical safety and less adverse reactions, it can effectively improve the level of cerebral nerve factors NSE and S-100 in children with FS, and has a good effect on brain protection.
|
|
|
|
|
|
[1] 易招师，钟建民，虞雄鹰，等.左乙拉西坦预防小儿热性惊厥复发的疗效和安全性[J].中华实用儿科临床杂志，2014，29（23）：1828-1830.
[2] 张润春，王玉珍，刘寅，等.不同剂量左乙拉西坦短期应用防治小儿热性惊厥的效果及对脑电图的影响[J].解放军医药杂志，2019，31（2）：98-101.
[3] 李学超，王建忠，张冬艳，等.左乙拉西坦联合丙戊酸钠或地西泮预防小儿热性惊厥反复发作的临床观察[J].中国药房，2016，27（29）：4106-4109.
[4] 杜雅坤，陈芳，王磊，等.左乙拉西坦对部分性癫痫患儿脑电图和认知功能的影响研究[J].中国全科医学，2019， 22（14）：1689-1695，1701.
[5] 郭虎，郑帼.热性惊厥处理指南解读[J].实用儿科临床杂志，2011，26（6）：467-468.
[6] Canpolat M，Per H，Gumus H，et al. Investigating the prevalence of febrile convulsion in Kayseri，Turkey：An assessment of the risk factors for recurrence of febrile convulsion and for development of epilepsy [J]. Seizure：the journal of the British Epilepsy Association，2018，55：36-47.
[7] 展晓玲，廖翠芳，何凯.小儿单纯性与复杂性热性惊厥临床特点及脑电图分析[J].中国医药科学，2019，9（10）：67-69.
[8] 姜春颖，滕紫藤，王丹，等.儿童复杂性热性惊厥285例多因素临床分析[J].中国实用儿科杂志，2018，33（10）：805-808.
[9] Rajab E，Abdeen Z，Hassan Z，et al. Cognitive performance and convulsion risk after experimentally-induced febrile-seizures in rat [J]. Int J Dev Neurosci，2014，34：19-23.
[10] 胡琳燕，邹丽萍，钟建民，等.口服左乙拉西坦即刻预防儿童热性惊厥的多中心随机对照研究[J].发育医学电子杂志，2015，3（2）：96-102.
[11] 万志坚.左乙拉西坦预防复杂性热性惊厥的疗效及不良反应的临床研究[J].泰山医学院学报，2016，37（8）：913-914.
[12] Inaba T，Miyamoto N，Hira K，et al. Protective Role of Levetiracetam Against Cognitive Impairment And Brain White Matter Damage in Mouse prolonged Cerebral Hypoperfusion [J]. Neuroscience，2019，21（414）：255-264.
[13] 周田，蒲利华，祝撷英.吡拉西坦联合左乙拉西坦治疗小儿癫痫的效果及对认知功能的影响[J].中国医药，2019， 14（9）：1340-1343.
[14] 将友信.左乙拉西坦预防小儿复杂性热性惊厥复发的疗效分析[J].国际医药卫生导报，2012，10（2）：632.
[15] 张前明，黄志，李劲松.左乙拉西坦预防复杂性热性惊厥的疗效及不良反应的临床研究[J].中国药学与临床，2015，15（8）：1126-1128.
[16] 刘国军.左乙拉西坦预防儿童热性惊厥复发的效果[J].实用临床医学，2015，22（3）：64-65.
[17] 张伟国.左乙拉西坦结合常规疗法治疗青年难治性部分性癫痫的效果及对患者认知功能、生活质量的影响[J].中国医药科学，2018，8（20）：44-47.
[18] 幸鸿宇，刘丕松，杨一海，等.左乙拉西坦治疗小儿癫痫的效果及对认知功能的影响[J].中国医药导报，2019， 16（27）：122-125.
[19] 申红爽，路童，徐善森，等.左乙拉西坦在中国癫痫患儿中的群体药代动力学研究[J].中国临床药理学杂志，2019，35（14）：1485-1488，1492.
[20] 毕文静，王媛.左乙拉西坦治疗小儿热性惊厥的临床疗效及对患儿免疫功能和复发的影响[J].国际医药卫生导报，2019，25（4）：616-619.
[21] 石筱蕾，王永清，杨文.惊厥患儿血清、脑脊液中神经元特异性烯醇化酶的临床意义[J].中南医学科学杂志，2016， 44（1）：48-50.
[22] Li Y，Yu ZX，Ji MS，et al. A Pilot Study of the Use of Dexmedetomidine for the Control of Delirium by Reducing the Serum Concentrations of Brain-Derived Neurotrophic Factor，Neuron-Specific Enolase，and S100B in Polytrauma Patients [J]. J Intensive Care Med，2019，34（8）：674-681.
[23] 尹芹，周圆圆.脑脊液中蛋白质标志物在中枢神经系统疾病中的表达分析[J].中国实用医刊，2019，46（12）：70-72.
[24] 苏保宁，苏海燕，朱红岩，等.热性惊厥儿童血清NSE、S-100β蛋白及Ca2+水平变化临床分析[J].中国妇幼保健，2015，30（28）：4818-4819. |
|
|
|
